Hypoxia-reinforced antitumor RNA interference mediated by micelleplexes with programmed disintegration
Source abstract
Abstract
The performance of polycation-mediated siRNA delivery is often hurdled by the multiple systemic and cellular barriers that pose conflicting requirements for materials properties. Herein, micelleplexes (MPs) capable of programmed disintegration were developed to mediate efficient delivery of siRNA against XIAP (siXIAP) in a hypoxia-reinforced manner. MPs were assembled from azobenzene-crosslinked oligoethylenimine (AO), acid-transformable diblock copolymer PPDHP with conjugated photosensitizer, and siXIAP. AO efficiently condensed siXIAP via electrostatic interaction, and PPDHP rendered additional hydrophobic interaction with AO to stabilize the MPs against salt. The hydrophilic PEG corona enhanced the serum stability of MPs to prolong blood circulation and promote tumor accumulation. After internalization into cancer cells, the endolysosomal acidity triggered shedding of PPDHP, exposing AO to induce endolysosomal escape. Then, light irradiation generated lethal amount of ROS, and concurrently aggravated intracellular hypoxia level to degrade AO into low-molecular weight segments, release siXIAP, and potentiate the XIAP silencing efficiency. Thus, siXIAP-mediated pro-apoptosis cooperated with generated ROS to provoke pronounced anti-cancer efficacy against Skov-3 tumors in vitro and in vivo. This study provides a hypoxia-instructed strategy to overcome the multiple barriers against anti-cancer siRNA delivery in a programmed manner. STATEMENT OF SIGNIFICANCE: The success of RNA interference (RNAi) heavily depends on delivery systems that can enable spatiotemporal control over siRNA delivery. Herein, we developed micelleplexes (MPs) constructed from hypoxia-degradable, azobenzene-crosslinked oligoethylenimine (AO) and acid-responsive, photosensitizer-conjugated diblock copolymer PPDHP, to mediate efficient anti-tumor siRNA (siXIAP) delivery via programmed disintegration. MPs possessed high salt/serum stability and underwent acid-triggered PPDHP detachment to promote endolysosomal escape. Then, light irradiation aggravated hypoxia to trigger AO degradation and intracellular siXIAP release, which cooperated with photodynamic therapy to eradicate tumor cells. This study presents a new example of hypoxia-degradable polycation to mediate hypoxia-reinforced RNAi, and it also renders an effective strategy to overcome the complicated extracellular/intracellular barriers against systemic siRNA delivery.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Therapeutic potential of RNA interference against cancer10.1111/j.1349-7006.2006.00234.x ↗
2. Altered RNA processing in cancer pathogenesis and therapy10.1158/2159-8290.CD-19-0399 ↗
3. Therapeutic siRNA: state of the art10.1038/s41392-020-0207-x ↗
4. L. Yin, α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery10.1016/j.addr.2020.12.007 ↗
5. Nano-based delivery of RNAi in cancer therapy10.1186/s12943-017-0683-y ↗
6. Platelet pharmacytes for the hierarchical amplification of anti-tumor immunity in response to self-generated immune signals10.1002/adma.202109517 ↗
7. Core role of hydrophobic core of polymeric nanomicelle in endosomal escape of siRNA10.1021/acs.nanolett.0c04468 ↗
8. Pro-peptide-reinforced, mucus-penetrating pulmonary siRNA delivery mitigates cytokine storm in pneumonia10.1002/adfm.202008960 ↗
9. Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment10.1002/EXP.20210008 ↗
10. Delivery materials for siRNA therapeutics10.1038/nmat3765 ↗
11. Fluorinated oligoethylenimine nanoassemblies for efficient siRNA-mediated gene silencing in serum-containing media by effective endosomal escape10.1021/acs.nanolett.8b02553 ↗
12. A pH-sensitive nanomedicine incorporating catalase gene and photosensitizer augments photodynamic therapy and activates antitumor immunity10.1016/j.nantod.2022.101390 ↗
13. Harnessing pH-sensitive polycation vehicles for the efficient siRNA delivery10.1021/acsami.0c17866 ↗
14. Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration10.1016/j.addr.2017.07.021 ↗
15. Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury10.1021/acs.nanolett.9b04957 ↗
16. Strategies to overcome the polycation dilemma in drug delivery10.1016/j.addr.2018.07.017 ↗
17. Synergistic microRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells10.1002/advs.201801809 ↗
18. Multifunctional cationic nanosystems for nucleic acid therapy of thoracic aortic dissection10.1038/s41467-019-11068-1 ↗
19. Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers10.1126/sciadv.aay7148 ↗
20. Multivalency-assisted membrane-penetrating siRNA delivery sensitizes photothermal ablation via inhibition of tumor glycolysis metabolism10.1016/j.biomaterials.2019.119463 ↗
21. Polymeric delivery of therapeutic nucleic acids10.1021/acs.chemrev.0c00997 ↗
22. Polycations and their biomedical applications10.1016/j.progpolymsci.2016.05.004 ↗
23. Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids10.1002/smll.201803061 ↗
24. Precise assembly of synthetic carriers of siRNA through a series of interlocked thermodynamically self-regulated processes10.1002/adfm.201703207 ↗
25. A hybrid nanovector of suicide gene engineered lentivirus coated with bioreducible polyaminoglycosides for enhancing therapeutic efficacy against glioma10.1002/adfm.201900922 ↗
26. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing10.1038/s41565-019-0539-2 ↗
27. Macrophage-targeting gene silencing orchestrates myocardial microenvironment remodeling toward the anti-inflammatory treatment of ischemia-reperfusion (IR) injury
28. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles10.1002/adma.201902575 ↗
29. An alternating irradiation strategy-driven combination therapy of PDT and RNAi for highly efficient inhibition of tumor growth and metastasis10.1002/adhm.202001850 ↗
30. Reversible treatment of pressure overload-induced left ventricular hypertrophy through Drd5 nucleic acid delivery mediated by functional polyaminoglycoside10.1002/advs.202003706 ↗
31. Far-red light-mediated programmable anti-cancer gene delivery in cooperation with photodynamic therapy10.1016/j.biomaterials.2018.04.020 ↗
32. Intracellularly disintegratable polysulfoniums for efficient gene delivery10.1002/adfm.201606826 ↗
33. Endothelial cell-targeting, ROS-ultrasensitive drug/siRNA co-delivery nanocomplexes mitigate early-stage neutrophil recruitment for the anti-inflammatory treatment of myocardial ischemia reperfusion injury10.1016/j.actbio.2022.02.018 ↗
34. Tailoring Hyperbranched Poly(β-amino ester) as a Robust and Universal Platform for Cytosolic Protein Delivery
35. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy10.1016/j.actbio.2021.09.040 ↗
36. ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy10.1016/j.actbio.2021.11.042 ↗
37. Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: an up-to-date review10.1016/j.jconrel.2019.12.041 ↗
38. Hypoxia-targeted drug delivery10.1039/C8CS00304A ↗
39. A general hypoxia-responsive molecular container for tumor-targeted therapy10.1002/adma.201908435 ↗
40. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery10.1016/j.biomaterials.2013.11.022 ↗
41. Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts10.1016/j.actbio.2018.10.029 ↗
42. Enzyme-instructed activation of pro-protein therapeutics in vivo10.1021/jacs.9b08669 ↗
43. Cytosolic NQO1 enzyme-activated near-infrared fluorescence imaging and photodynamic therapy with polymeric vesicles10.1021/acsnano.9b08285 ↗
44. Biomimetic, hypoxia-responsive nanoparticles overcome residual chemoresistant leukemic cells with co-targeting of therapy-induced bone marrow niches10.1002/adfm.202000309 ↗
45. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy10.1002/adma.201901513 ↗
46. Hypoxia-degradable zwitterionic phosphorylcholine drug nanogel for enhanced drug delivery to glioblastoma10.1016/j.cej.2020.127359 ↗
47. Azo-inserted responsive hybrid liposomes for hypoxia-specific drug delivery10.1016/j.actbio.2020.07.061 ↗
48. Hypoxia-targeted siRNA delivery10.1002/anie.201308368 ↗
49. Targeting hypoxia in cancer therapy10.1038/nrc3064 ↗
50. Boosting O2•− photogeneration via promoting intersystem-crossing and electron-donating efficiency of aza-BODIPY-based nanoplatforms for hypoxic-tumor photodynamic therapy10.1002/smtd.202000013 ↗
51. A mitochondrial oxidative stress amplifier to overcome hypoxia resistance for enhanced photodynamic therapy10.1002/smtd.202100581 ↗
52. Engineering oxygen-irrelevant radical nanogenerator for hypoxia-independent magnetothermodynamic tumor nanotherapy10.1002/smtd.202001087 ↗
53. Combinatorial approach to nanoarchitectonics for nonviral delivery of nucleic acids10.1002/adma.201502888 ↗
54. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
55. Bottlebrush-architectured poly(ethylene glycol) as an efficient vector for RNA interference in vivo10.1126/sciadv.aav9322 ↗
56. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo10.1038/s41467-021-27078-x ↗
57. Intratumor performance and therapeutic efficacy of PAMAM dendrimers carried by clustered nanoparticles10.1021/acs.nanolett.9b03913 ↗
58. Efficient near-infrared photosensitizer with aggregation-induced emission for imaging-guided photodynamic therapy in multiple xenograft tumor models10.1021/acsnano.9b07972 ↗
59. Targeting XIAP for promoting cancer cell death-the story of ARTS and SMAC10.3390/cells9030663 ↗
60. Hypoxia-mediated decrease of ovarian cancer cells reaction to treatment: significance for chemo- and immunotherapies10.3390/ijms21249492 ↗
61. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine10.1073/pnas.92.16.7297 ↗
62. Carriers break barriers in drug delivery: endocytosis and endosomal escape of gene delivery vectors10.1021/acs.accounts.9b00177 ↗
63. Self-assembling properties of well-defined poly(ethylene oxide)-b-poly(ethyl acrylate) diblock copolymers10.1021/ma802705b ↗
64. Hypoxia-induced pro-protein therapy assisted by a self-catalyzed nanozymogen10.1002/anie.202004008 ↗